Market Overview

PetMed Express d/b/a 1-800-PetMeds Announces Its Second Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.27 per Share


Quarterly Reorder Sales Increased 1.4%
Gross Margins Improved Sequentially from 27.3% to 28.6%
Operating Margins Increased 430 Basis Points Sequentially

DELRAY BEACH, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ:PETS) today announced its financial results for the quarter ended September 30, 2019.  Net sales for the quarter ended September 30, 2019 were $69.9 million, compared to $71.4 million for the quarter ended September 30, 2018, a decrease of 2.0%.  Net income was $6.7 million, or $0.33 diluted per share, for the quarter ended September 30, 2019, compared to net income of $10.8 million, or $0.52 diluted per share, for the quarter ended September 30, 2018, a 36% decrease in diluted earnings per share.  Reorder sales increased 1.4%, to $61.9 million for the quarter ended September 30, 2019, compared to $61.0 million for the same quarter in the prior year. 

Menderes Akdag, CEO and President, commented: "We were encouraged with improvements to our reorder sales and gross and operating margins during the quarter. Gross margins improved by 130 basis points from 27.3% in the June quarter to 28.6% in the September quarter, and operating margins improved by 430 basis points from 7.7% in the June quarter to 12.0% in the September quarter.  The gross margin increase can be attributed to our success in obtaining direct purchasing relationships with the major manufacturers, and the implementation of the minimum advertised price (MAP) policy by some of the major manufacturers.  We anticipate MAP pricing to stabilize pet medication prices throughout the online channel.  We made further progress in October, and we now have direct relationships with all of the major manufacturers, which may help further improve our gross margins in the future.  We are also pleased to announce that on September 1st we launched our new PetMeds® Rewards Program.  This customer loyalty program allows our customers to accrue points to receive additional discounts on future orders.  This program will increase our engagement with our customer base and should help promote future reorder sales.  Net cash from operations for the six months ended September 30, 2019 was $17.3 million, compared to $20.4 million for the same period last year.  In fiscal 2020, we will continue to be price competitive and will focus on optimizing our marketing in this more competitive environment and being more efficient with our advertising spending.  In addition, we will be investing in our e-commerce platform to better service our customers.  This platform will enable us to improve upon our already strong net promoter score of 83.5%.  We believe this customer satisfaction measure reflects the strong bond we have with our customers and will assist the Company with future customer retention."

The Board of Directors declared a quarterly dividend of $0.27 per share on the Company's common stock.  The dividend will be payable on November 15, 2019, to shareholders of record at the close of business on November 4, 2019.  The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company's financial performance.

This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter's financial results.  To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (203) 827-7025.  Callers will be required to supply PETMEDS as the passcode.  For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. on October 21, 2019 until November 4, 2019 at 10:59 P.M Eastern Time.  To access the replay, call (800) 839-2310 (toll free) or (203) 369-3635, and enter passcode 5500.

Founded in 1996, PetMed Express is America's Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs, cats, and horses at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at

This press release may contain "forward-looking" statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company's ability to meet the objectives included in its business plan.  Important factors that could cause results to differ materially from those indicated by such "forward-looking" statements are set forth in Management's Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2019.  The Company's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.  For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.

(In thousands)
    September 30,   March 31,
    2019   2019
ASSETS   (Unaudited)    
Current assets:        
Cash and cash equivalents $ 94,897 $ 100,529
Accounts receivable, less allowance for doubtful        
accounts of $22 and $39, respectively   1,466   2,542
Inventories - finished goods   19,061   21,370
Prepaid expenses and other current assets   2,841   1,408
Prepaid income taxes   -   582
Total current assets   118,265   126,431
Noncurrent assets:        
Property and equipment, net   26,412   27,136
Intangible assets   860   860
Total noncurrent assets   27,272   27,996
Total assets $ 145,537 $ 154,427
Current liabilities:        
Accounts payable $ 15,155 $ 16,275
Accrued expenses and other current liabilities   2,871   2,351
Income taxes payable   525   -
Total current liabilities   18,551   18,626
Deferred tax liabilities   1,395   1,121
Total liabilities   19,946   19,747
Commitments and contingencies        
Shareholders' equity:        
Preferred stock, $.001 par value, 5,000 shares authorized;        
3 convertible shares issued and outstanding with a        
liquidation preference of $4 per share   9   9
Common stock, $.001 par value, 40,000 shares authorized;        
20,175 and 20,674 shares issued and outstanding, respectively   20   21
Additional paid-in capital   2,347   12,478
Retained earnings   123,215   122,172
Total shareholders' equity   125,591   134,680
Total liabilities and shareholders' equity $ 145,537 $ 154,427

(In thousands, except for per share amounts) (Unaudited)
    Three Months Ended   Six Months Ended
    September 30,   September 30,
    2019   2018   2019   2018
Sales $ 69,936 $ 71,396 $ 149,924 $ 158,786
Cost of sales   49,934   46,141   108,061   103,577
Gross profit   20,002   25,255   41,863   55,209
Operating expenses:                
View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at